Hepatitis C News

Resistance-guided direct-acting antiviral retreatment resulted in nearly 90% sustained virologic response rates among patients with hepatitis C who developed resistance-associated substitutions after failing treatment with NS5A inhibitors.

Researchers discovered that an elevated fatty liver index was an independent risk factor for all-cause mortality in patients coinfected with hepatitis C and HIV, regardless of liver fibrosis or sustained virologic response to hepatitis therapy.

The FDA approved changes to the labeling of direct-acting antivirals Sovaldi and Harvoni to include information on dosage and administration in pediatric patients with hepatitis C aged 3 years to younger than 12 years.

The FDA has received reports that the use of Mavyret, Zepatier or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver disease has resulted in rare cases of liver injury or liver failure, according to a drug safety communication.

The U.S. Preventive Services Task Force has issued a draft recommendation that encourages clinicians to screen all adults aged 18 to 79 years for hepatitis C virus infection.

Sustained virologic response after treatment for hepatitis C correlated with a reduced risk for several extrahepatic manifestations including type 2 diabetes, chronic kidney disease, and mood and anxiety disorders.

In a follow-up analysis of participants in clinical trials, researchers found that patient-reported outcome scores increased in patients who achieved sustained virologic response after treatment for hepatitis C, whereas scores decreased in those who did not.

Scaling up access to direct-acting antivirals, or DAAs, is the most cost-effective intervention for reducing hepatitis C virus among people who inject drugs when only health sector costs are considered, according to findings from a computer simulation study.

Most patients with hepatitis C in Africa have genotypes outside of the common and easily cured genotype 1a and genotype 1b, which has led to a suboptimal rate of sustained virologic response.

Treatment with Vosevi, a combination of sofosbuvir, velpatasvir and voxilaprevir, was an effective and safe therapy for patients with prior direct-acting antiviral treatment failure, according to findings published in the Journal of Hepatology.